A multi-centre study led by the University Hospital Hamburg-Eppendorf (UKE) is evaluating one of the first personalised approaches for moderate to sever.
A multi-center study led by UKE is evaluating one of the first personalized approaches for moderate to severe COVID-19 patients.The innovative biomarkers bio-ADM and DPP3 are guiding the enrollment of
Dipeptidyl Peptidase 3 Biomarker to Drive Precision Medicine in COVID-19 theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Biomarker-Guided Trial Led by University Hospital Hamburg-Eppendorf (UKE) Opens New Avenues for Personalized Medicine in COVID-19 saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Issuer: 4TEEN4 Pharmaceuticals GmbH / Key word(s): Study 11.04.2022 / 11:00 The issuer is solely responsible for the content of this announcement. Dipeptidyl Peptidase 3 release is